Eyenovia, Inc.

Home
United States
New York, NY
Eyenovia, Inc.

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Eyenovia, Inc., Pharmaceutical Company, 295 Madison Avenue, Suite 2400, New York, NY.

Eyenovia is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology.

11/12/2024

Indianapolis is now best known for the INDY500 and Eyenovia’s 2024 Ad Board!

Eyenovia had the privilege of engaging with a distinguished group of optometric leaders at our American Academy of Optometry advisory board meeting. Together, we explored the transformative potential of Clobetasol to revolutionize eye care, along with the exciting future of MydCombi. The insightful discussions provided valuable perspectives that will help us accelerate launch developments for the next-generation ophthalmic steroid and more innovative solutions.

We are deeply grateful for the time, expertise, and passion our advisors share. Your guidance is vital as we continue to push boundaries and advance the future of eye care. Thank you for joining us on this journey!

Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com

Interested in more information and how to get MydCombi? mydcombi.com

Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca

11/08/2024

Discover the future of pupil dilation at AAOpt 2024 with a Phase 4 study on MydCombi! Led by Josianne Manasse, OD and Denise Pensyl, OD from SUNY College of Optometry.

When: Friday, November 8, 2024
Where: AAOpt - Indianapolis
Location: Exhibit Hall H, Poster Board #109
Time: 1:00-3:00 PM

Learn more about MydCombi: https://bit.ly/mydcombi

Contraindications: Known hypersensitivity to any component of the formulation.
See Full Prescribing Information Here:
https://bit.ly/4btbPHk”

Learn how Eyenovia is making it possible by visiting https://bit.ly/3Dik87F

10/31/2024

Shelley Malkemus, a legend in ophthalmology, is happily heading to retirement! After years of dedication, attention to detail, and countless moments of support for the Eyenovia team and the industry, Shelley is officially closing this chapter of her remarkable career.

But don’t think she’s slowing down! Shelley is taking on a brand-new role as a full-time Grammy, stepping into her next adventure with open arms as her family grows and welcomes another precious grandchild.

Thank you, Shelley, for everything you’ve done to keep us on track and inspired. We wish you all the best in this exciting new phase—one that comes with more hugs, playdates, and plenty of love. 💙 Happy Retirement, Shelley!

10/30/2024

Blink, and it’s gone! It’s been just over a week since the American Academy of Ophthalmology, and Eyenovia extends its sincere thanks to the ophthalmic leaders who attended our AAO 2024 Advisory Board in Chicago. The thoughtful and engaging discussions surrounding our products were invaluable, providing key insights that will help propel the momentum behind our commercial launches of Clobetasol and MydCombi even further. We are excited to incorporate these perspectives as we continue to advance our portfolio. Thank you once again to our esteemed advisors for an evening of productive discussion and shared learning!

Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com

Interested in more information and how to get MydCombi? mydcombi.com

Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca

10/18/2024

Thank you, Francis Mah, MD, for being among the early adopters of Clobetasol, the next-generation ophthalmic steroid! We are pleased to see that you are actively prescribing Clobetasol for your patients. Renowned for his contributions as an ophthalmologist and respected researcher, speaker, and thought leader, Dr. Mah is dedicated to enhancing patient outcomes through innovative treatment approaches. Clobetasol empowers him to deliver powerful, swift relief from post-surgical pain and inflammation. With twice-a-day dosing, this state-of-the-art treatment has the potential to deliver quicker recovery times and improved overall patient experience.

Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/

Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca

INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Full Prescribing Information: https://lnkd.in/gWYjgSiN

10/10/2024

Dagny Zhu, M.D. — — the Medical Director and Partner of NVISION Eye Centers Rowland Heights, was one of the first in the US to implement Clobetasol into her practice and post-operative patient care. She stated, “I’m excited for the ease of twice-a-day dosing for our patients. I also look forward to using Clobetasol to treat postop inflammation in our surgical patients with greater peace of mind as the data suggests a low risk of IOP spikes.”

As a key opinion leader in advanced cataract surgery and LASIK surgery, Dr. Zhu has been featured in over 200 lectures, presentations, publications, and press features. We are thrilled to have an expert like herself using Clobetasol!

Learn more about NVISION and Dr. Zhu: https://lnkd.in/gJ5rfZbQ

Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/

Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca

INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Full Prescribing Information: https://lnkd.in/gWYjgSiN

Address

295 Madison Avenue, Suite 2400
New York, NY
10017

Telephone

+19172891117

Website

http://www.eyenoviabio.com/

Alerts

Be the first to know and let us send you an email when Eyenovia, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Eyenovia, Inc.:

Shortcuts

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?